Clinical Trial Update: Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy [Phase 2]

View source ↗

Summary

Phase 2 study of erlotinib in non-metastatic prostate cancer with rising PSA on hormone therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Endeavor Health | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED